Briumvi

Drug Overview

Briumvi is a highly advanced prescription medication utilized within the Neurology specialty. It belongs to the Anti-CD20 Monoclonal Antibody drug class. As a state-of-the-art Biologic and Immunotherapy, it is used to manage and alter the long-term course of multiple sclerosis (MS). Rather than broadly suppressing the entire immune system, this Targeted Therapy zeroes in on one specific type of white blood cell responsible for nerve damage. A major advantage of Briumvi is its specialized chemical design, which allows for a highly effective, fast one-hour maintenance infusion.

• Generic Name: Ublituximab (specifically ublituximab-xiiy)
  
• US Brand Names: BRIUMVI®
  
• Route of Administration: Intravenous (IV) Infusion
  
• FDA Approval Status: Fully FDA-approved in the United States (December 2022) and by the European Medicines Agency (EMA) for the treatment of relapsing forms of multiple sclerosis in adults.
  

What Is It and How Does It Work? (Mechanism of Action)

In multiple sclerosis, your immune system mistakenly attacks the myelin sheath, the protective fatty coating wrapped around the nerves in your brain and spinal cord. Medical research has proven that a specific type of white blood cell, called a B-cell, acts as the “commander” organizing these attacks.

Briumvi is a laboratory-engineered Smart Drug designed to hunt down and eliminate these aggressive B-cells.

At the molecular and cellular levels, Briumvi works through a highly precise, “glycoengineered” process:

• Finding the Target (CD20): Briumvi circulates in your bloodstream and binds to a specific marker called the CD20 receptor. This receptor is found almost exclusively on the surface of mature B-cells.
  
• The Glycoengineered Advantage: What makes Briumvi unique is how it is built. Scientists removed a specific sugar molecule (called fucose) from the drug’s structure. This “missing sugar” makes the drug act like a super-magnet for the body’s Natural Killer (NK) cells.
  
• Cellular Destruction (ADCC): Once Briumvi tags the B-cell, it strongly attracts these Natural Killer cells. This process, called Antibody-Dependent Cellular Cytotoxicity (ADCC), causes the NK cells to puncture and destroy the tagged B-cell.
  
• Brain Protection: By quickly clearing these rogue B-cells out of the blood and lymph nodes, they can no longer cross the blood-brain barrier to trigger nerve-damaging inflammation. Importantly, because stem cells in the bone marrow do not have the CD20 marker, your body can eventually rebuild a new, healthy supply of B-cells.
  

FDA-Approved Clinical Indications

• Primary Indication: Relapsing forms of Multiple Sclerosis (RMS). Briumvi is FDA-approved to treat relapsing forms of multiple sclerosis in adults. This includes Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), and active Secondary Progressive MS (SPMS). (Note: As clarified above, it is used for maintenance prevention, not acute rescue during a sudden attack).
  
• Other Approved Uses:
  • 
    Currently, the Briumvi brand is strictly approved for neurological use in MS.
    
  • 
    Earlier, different formulations of ublituximab were heavily researched in oncology for blood cancers (like Chronic Lymphocytic Leukemia), taking advantage of the same B-cell clearing mechanism.
    

Dosage and Administration Protocols

Briumvi is given as an intravenous (IV) infusion through a vein in your arm at a hospital or specialized infusion center. Because it is highly potent, the very first dose is split into two smaller infusions to help your body adjust. Afterward, maintenance doses are given only twice a year.

Dose Adjustments

• Pre-Medication: Because destroying B-cells can cause a physical reaction, you must be given a corticosteroid (like methylprednisolone) and an antihistamine (like diphenhydramine) about 30 to 60 minutes before every single infusion.
  
• Renal Insufficiency (Kidney Problems): Because this is a large antibody protein, it is not processed by the kidneys. No dose adjustments are needed for kidney disease.
  
• Hepatic Insufficiency (Liver Problems): No dose adjustments are needed for liver issues.
  
• Infusion Reactions: If you develop fever, chills, or difficulty breathing during the drip, the nurse will immediately slow down or pause the IV until you feel better.
  

Clinical Efficacy and Research Results

The FDA approval of Briumvi was based on the massive ULTIMATE I and ULTIMATE II clinical trials (published in 2022). These trials compared Briumvi directly to an older oral MS drug called teriflunomide.

• Fewer Relapses: Patients receiving this Immunotherapy had remarkably low Annualized Relapse Rates (ARR) of just 0.076 and 0.091. This means, on average, a patient would experience less than one MS attack every ten years. This represented a nearly 60% reduction in relapses compared to the older pill.
  
• Massive Reduction in Brain Scarring: Routine MRI scans showed that Briumvi reduced the formation of new, active brain lesions (areas of severe inflammation) by a staggering 97%.
  
• Quality of Life: By nearly halting new damage, patients showed excellent stability in their physical disability scores, allowing them to maintain their mobility and independence over the years.
  

Safety Profile and Side Effects

Black Box Warning: Briumvi is considered highly effective and does not carry a formal FDA “Black Box” warning. However, the label contains severe warnings regarding Hepatitis B virus reactivation and serious infections.

Common Side Effects (>10%)

• Infusion Reactions: Up to 48% of patients experience a reaction during or within 24 hours of the infusion. Symptoms include fever, chills, headache, nausea, and an itchy throat. This is most common during the very first dose.
  
• Upper Respiratory Infections: Common colds, sinus infections, and sore throats.
  

Serious Adverse Events

• Hepatitis B Reactivation: If you carry the Hepatitis B virus, this drug can cause the virus to wake up and cause sudden, severe liver failure.
  
• Severe Infections: Because the drug lowers your B-cells, your body has a harder time fighting off serious bacterial or viral infections.
  
• Low Immunoglobulins: A drop in certain blood proteins that help fight infection, which may require monitoring.
  
• Progressive Multifocal Leukoencephalopathy (PML): A very rare but potentially fatal brain infection caused by the JC virus. While rare, it is a known risk for immune-suppressing drugs.
  

Management Strategies

• Managing Infusion Reactions: Always take the pre-medications provided by your nurse. If you feel dizzy, itchy, or short of breath during the IV drip, tell the nurse immediately so they can slow the medicine down.
  
• Infection Vigilance: You must practice good hand hygiene and avoid contact with people who are visibly sick.
  

Connection to Stem Cell and Regenerative Medicine

In the growing field of regenerative neurology, clearing away toxic inflammation is a mandatory first step before the brain can be repaired. Because multiple sclerosis actively destroys myelin, researchers are looking at ways to rebuild it using stem cells. While a Targeted Therapy like Briumvi does not grow new myelin on its own, it creates a safe environment (a “niche”) in the brain and spinal cord. Current medical research (2024–2026) investigates how using B-cell depleting therapies to quiet the immune system’s attack acts as a biological shield. It is believed that preparing the brain with a drug like Briumvi could allow newly implanted mesenchymal stem cells to survive, take root, and begin repairing the nervous system without being instantly destroyed by the patient’s own aggressive B-cells.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Hepatitis B Screening: This is an absolute requirement. You must have a blood test to check for Hepatitis B surface antigen and core antibodies before you can start this medicine.
  
• Immunoglobulin Blood Test: A baseline blood test to check the levels of natural infection-fighting proteins in your blood (IgG and IgM).
  
• Pregnancy Test: For women of childbearing age, to ensure you are not pregnant before starting therapy.
  

Precautions During Treatment

• Vaccines: You cannot receive live or live-attenuated vaccines while on Briumvi. Any necessary live vaccines must be given at least 4 weeks before starting treatment. Non-live vaccines (like the flu or COVID-19 shot) should be given at least 2 weeks before your next scheduled infusion.
  
• Infection Monitoring: If you develop a fever, persistent cough, or burning during urination, you must call your doctor right away, as these could be signs of an infection that needs antibiotics.
  

Do’s and Don’ts

• DO drink plenty of water the day before and the morning of your infusion to help the nurse find a vein easily.
  
• DO plan to have someone drive you home after your very first infusion, as the pre-medications (like antihistamines) can make you very sleepy.
  
• DO use effective birth control while taking this medication and for at least 6 months after your last infusion, as it may harm an unborn baby.
  
• DON’T go to your infusion appointment if you currently have a fever or an active infection; your doctor will likely reschedule it until you are healthy.
  
• DON’T stop your medication schedule just because you feel well. Briumvi works in the background to prevent future attacks.
  

Legal Disclaimer

The information provided in this medical guide is for educational and informational purposes only and does not replace professional medical advice. Briumvi (ublituximab) is a powerful immune-modulating medication that requires close monitoring, specific baseline testing, and administration by a qualified healthcare professional. Treatment protocols, dosages, and side-effect management may vary depending on your specific health history and regional guidelines. Always consult with a licensed healthcare professional regarding your diagnosis, treatment options, and whether this medication is appropriate for your individual medical needs.